Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 3736201, 6 pages
https://doi.org/10.1155/2017/3736201
Review Article

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials

1Postgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, RN, Brazil
2Department of Gynecology and Obstetrics, University Potiguar (UnP), Natal, RN, Brazil
3Department of Gynecology and Obstetrics, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil
4Department of Gynecology and Obstetrics, State University of Campinas (UNICAMP), Campinas, SP, Brazil

Correspondence should be addressed to Ricardo Ney Oliveira Cobucci; moc.liamtoh@iccubocnr

Received 24 February 2017; Revised 9 May 2017; Accepted 4 June 2017; Published 24 July 2017

Academic Editor: Angelika Riemer

Copyright © 2017 Ana Paula Ferreira Costa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Walboomers, M. V. Jacobs, M. M. Manos et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” The Journal of Pathology, vol. 189, pp. 12–19, 1999. View at Publisher · View at Google Scholar
  2. S. Sanjose, W. G. Quint, L. Alemany et al., “Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study,” The Lancet Oncology, vol. 11, pp. 1048–1056, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. K. Kjaer, T. N. Tran, P. Sparen et al., “The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries,” The Journal of Infectious Diseases, vol. 196, pp. 1447–1454, 2007. View at Google Scholar
  4. S. M. Garland, M. Steben, H. L. Sings et al., “Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine,” The Journal of Infectious Diseases, vol. 199, pp. 805–814, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. D. Christensen, “Emerging human papillomavirus vaccines,” Expert Opinion on Emerging Drugs, vol. 10, pp. 5–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. E. A. Joura, A. R. Giuliano, O. E. Iversen et al., “A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women,” The New England Journal of Medicine, vol. 372, pp. 711–723, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Luna, M. Plata, M. Gonzalez et al., “Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women,” PLoS One, vol. 8, no. 12, article e83431, 2013. View at Google Scholar
  8. D. Y. Yang, “Update on the new 9-valent vaccine for human papillomavirus prevention,” Canadian Family Physician, vol. 62, pp. 399–402, 2016. View at Google Scholar
  9. A. K. Gonçalves, R. N. Cobucci, H. M. Rodrigues, A. G. de Melo, and P. C. Giraldo, “Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review,” The Brazilian Journal of Infectious Diseases, vol. 18, no. 6, pp. 651–659, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. B. A. Slade, L. Leidel, C. Vellozzi et al., “Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine,” JAMA, vol. 302, no. 7, pp. 750–757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Gee, A. Naleway, I. Shui et al., “Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink,” Vaccine, vol. 29, pp. 8279–8284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLoS Medicine, vol. 6, no. 7, article e1000097, 2009. View at Google Scholar
  13. J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, pp. 557–560, 2003. View at Publisher · View at Google Scholar
  14. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  15. A. R. Jadad, R. A. Moore, D. Caroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. Harris, M. J. Bradburn, J. J. Deeks, R. M. Harbord, D. G. Altman, and J. A. C. Sterne, “Metan: fixed- and random-effects meta-analysis,” The Stata Journal, vol. 8, pp. 3–28, 2008. View at Google Scholar
  17. T. Vesikari, N. Brodszki, P. Van Damme et al., “A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls,” The Pediatric Infectious Disease Journal, vol. 34, no. 9, pp. 992–998, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. E. D. Moreira Jr., S. L. Block, D. Ferris et al., “Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials,” Pediatrics, vol. 138, no. 2, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Van Damme, S. E. Olsson, S. Block et al., “Immunogenicity and safety of a 9-valent HPV vaccine,” Pediatrics, vol. 136, no. 1, pp. e28–e39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Schilling, M. M. Parra, M. Gutierrez et al., “Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines,” Pediatrics, vol. 136, no. 3, pp. e563–e572, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Castellsagué, A. R. Giuliano, S. Goldstone et al., “Immunogenicity and safety of the 9-valent HPV vaccine in men,” Vaccine, vol. 33, no. 48, pp. 6892–6901, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Iwata, S. Murata, S. R. Han, A. Wakana, M. Sawata, and Y. Tanaka, “Safety and immunogenicity study of a 9-valent human papillomavirus vaccine administered to 9-to-15 year-old Japanese girls,” Japanese Journal of Infectious Diseases, 2016. View at Publisher · View at Google Scholar